{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:04:22Z","timestamp":1774339462982,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s13760-019-01098-3","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T04:40:35Z","timestamp":1551847235000},"page":"423-430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lacosamide in patients with intellectual disability and refractory epilepsy"],"prefix":"10.1007","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0062-8976","authenticated-orcid":false,"given":"Anika","family":"Kleist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Kerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajo","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Winterholler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"1098_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S0011-5029(03)00065-8","volume":"49","author":"B Shneker","year":"2003","unstructured":"Shneker B, Fountain N (2003) Epilepsy. Dis Mon 49:426\u2013478","journal-title":"Dis Mon"},{"issue":"9","key":"1098_CR2","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/j.1528-1157.2000.tb00328.x","volume":"41","author":"E Airaksinen","year":"2000","unstructured":"Airaksinen E, Matilainen R, Mononen T, Mustonen K, Partanen J, Jokela V et al (2000) A population-based study on epilepsy in mentally retarded children. Epilepsia 41(9):1214\u20131220","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"1098_CR3","first-page":"1","volume":"42","author":"N Alvarez","year":"1998","unstructured":"Alvarez N, Besag F, Iivanainen M (1998) Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res 42(Suppl 1):1\u201315","journal-title":"J Intellect Disabil Res"},{"key":"1098_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S1525-5050(02)00002-1","volume":"3","author":"G Gibson","year":"2002","unstructured":"Gibson G (2002) Efficacy of levetiracetam in developmentally disabled patients: a review of the literature and six case reports. Epilepsy Behav 3:280\u2013284","journal-title":"Epilepsy Behav"},{"key":"1098_CR5","doi-asserted-by":"publisher","first-page":"331336","DOI":"10.1016\/S1059-1311(97)80032-5","volume":"6","author":"M Kerr","year":"1997","unstructured":"Kerr M, Espie C (1997) Learning disability and epilepsy, 1: towards common outcome measures. Seizure 6:331\u2013336","journal-title":"Seizure"},{"issue":"8","key":"1098_CR6","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.neuropharm.2006.02.002","volume":"50","author":"S Errington","year":"2006","unstructured":"Errington S, Coyne L, St\u00f6hr T, Selve N, Lees G (2006) Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 50(8):1016\u20131029 (abstract)","journal-title":"Neuropharmacology"},{"key":"1098_CR7","first-page":"479","volume":"6","author":"C Hovinga","year":"2003","unstructured":"Hovinga C (2003) SPM-927 (Schwarz Pharma). IDrugs 6:479\u2013485","journal-title":"IDrugs"},{"issue":"1","key":"1098_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.eplepsyres.2006.10.008","volume":"73","author":"M Bialer","year":"2007","unstructured":"Bialer M, Johannessen S, Kupferberg H, Levy R, Perucca E, Tomson T (2007) Progress report on the new antiepileptic drugs: a summary of the EILAT Conference (EILAT VIII). Epilepsy Res 73(1):1\u201352 (abstract)","journal-title":"Epilepsy Res"},{"key":"1098_CR9","first-page":"188","volume":"43","author":"R Horstmann","year":"2002","unstructured":"Horstmann R, Bonn R, Cawello W, Doty P, Rudd G (2002) Basic clinical pharmacological investigations of the new antiepileptic drug SPM-927. Epilepsia 43:188","journal-title":"Epilepsia"},{"key":"1098_CR10","first-page":"200","volume":"47","author":"D Thomas","year":"2006","unstructured":"Thomas D, Scharfenecker U, Nickel B, Doty P, Cawello W, Horstmann R (2006) Low potential for drug-drug interactions of lacosamide. Epilepsia 47:200","journal-title":"Epilepsia"},{"key":"1098_CR11","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.jpain.2006.01.253","volume":"7","author":"D Kropeit","year":"2006","unstructured":"Kropeit D (2006) Lacosamide has low potential for drug-drug interaction. J Pain 7:S63 (abstract 851)","journal-title":"J Pain"},{"issue":"7","key":"1098_CR12","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","volume":"48","author":"E Ben-Menachem","year":"2007","unstructured":"Ben-Menachem E, Biton V, Abou-Khalil B, Doty P, Rudd D (2007) Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48(7):1308\u20131317","journal-title":"Epilepsia"},{"issue":"6","key":"1098_CR13","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","volume":"51","author":"S Chung","year":"2010","unstructured":"Chung S, Sperling M, Biton V, Krauss G, Rudd G, Doty P, SP754 Study Group (2010) Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 51(6):958\u2013967","journal-title":"Epilepsia"},{"issue":"3","key":"1098_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","volume":"50","author":"P Hal\u00e1sz","year":"2009","unstructured":"Hal\u00e1sz P, K\u00e4lvi\u00e4inen R, Mazurkiewicz-Beldzi\u0144ska M, Rosenow F, Doty P, Hebert D et al (2009) Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 50(3):443\u2013453","journal-title":"Epilepsia"},{"key":"1098_CR15","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.7717\/peerj.114","volume":"1","author":"S Sawh","year":"2013","unstructured":"Sawh S, Newman J, Deshpande S, Jones P (2013) Lacosamide adjunctive therapy for partial-onset seizures: a meta-analysis. PeerJ 1:e114","journal-title":"PeerJ"},{"key":"1098_CR16","first-page":"CD008841","volume":"6","author":"J Weston","year":"2015","unstructured":"Weston J, Shukralla A, McKay AJ, Marson AG (2015) Lacosamide add-on therapy for partial epilepsy. Cochrane Database Syst Rev 6:CD008841 (abstract)","journal-title":"Cochrane Database Syst Rev"},{"key":"1098_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","volume":"52","author":"V Biton","year":"2015","unstructured":"Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain N (2015) Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav 52:119\u2013127","journal-title":"Epilepsy Behav"},{"issue":"12","key":"1098_CR18","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1111\/epi.13224","volume":"56","author":"U Runge","year":"2015","unstructured":"Runge U, Arnold S, Brandt C, Reinhardt F, K\u00fchn F, Isensee K et al (2015) A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: the VITOBA study. Epilepsia 56(12):1921\u20131930 (abstract)","journal-title":"Epilepsia"},{"issue":"3","key":"1098_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/WNF.0b013e318255b649","volume":"35","author":"R Andrade-Machado","year":"2012","unstructured":"Andrade-Machado R, Benjumea-Cuartas V, Jaramillo-Jimenez E (2012) Lacosamide in Lennox-Gastaut syndrome: case report. Clin Neuropharmacol 35(3):148\u2013149 (abstract)","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"1098_CR20","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.yebeh.2010.09.024","volume":"19","author":"A Cuzzola","year":"2010","unstructured":"Cuzzola A, Ferlazzo E, Italiano D, Calabr\u00f2 R, Bramanti P, Genton P (2010) Does lacosamide aggravate Lennox-Gastaut syndrome? Report on three consecutive cases. Epilepsy Behav 19(4):650\u2013651 (abstract)","journal-title":"Epilepsy Behav"},{"issue":"10","key":"1098_CR21","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/epi.13869","volume":"58","author":"S B\u00f6ttcher","year":"2017","unstructured":"B\u00f6ttcher S, Lutz M, Mayer T (2017) Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: a long-term study of 136 patients. Epilepsia 58(10):1749\u20131754","journal-title":"Epilepsia"},{"key":"1098_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.seizure.2015.10.009","volume":"33","author":"R Andrade-Machado","year":"2015","unstructured":"Andrade-Machado R, Luque-Navarro-de Los Reyes J, Benjumea-Cuartas V, Restrepo J, Jaramillo-Jim\u00e9nez E, Andrade-Gutierrez G et al (2015) Efficacy and tolerability of add-on Lacosamide treatment in adults with Lennox-Gastaut syndrome: an observational study. Seizure 33:81\u201387 (abstract)","journal-title":"Seizure"},{"issue":"7","key":"1098_CR23","doi-asserted-by":"publisher","first-page":"512517","DOI":"10.1016\/j.seizure.2012.05.005","volume":"21","author":"L Flores","year":"2012","unstructured":"Flores L, Kemp S, Colbeck K, Moran N, Quirk J, Ramkolea P et al (2012) Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicenter study in epilepsy clinics in the United Kingdom (UK). Seizure 21(7):512\u2013517","journal-title":"Seizure"},{"issue":"6","key":"1098_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/ane.12221","volume":"129","author":"S Grosso","year":"2014","unstructured":"Grosso S, Coppola G, Cusmai R, Parisi P, Spalice A, Foligno S et al (2014) Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome. Acta Neurol Scand 129(6):420\u2013424 (abstract)","journal-title":"Acta Neurol Scand"},{"key":"1098_CR25","first-page":"638","volume":"65","author":"M Linden","year":"1994","unstructured":"Linden M, Baier D, Beitinger H, Kohnen R, Osterheider M, Philipp M et al (1994) Leitlinien zur Durchf\u00fchrung von Anwendungsbeobachtungen in der Psychopharmakotherapie. Der Nervenarzt 65:638\u2013644","journal-title":"Der Nervenarzt"},{"issue":"4","key":"1098_CR26","doi-asserted-by":"publisher","first-page":"512521","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L et al (2017) ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58(4):512\u2013521","journal-title":"Epilepsia"},{"key":"1098_CR27","unstructured":"Guy W (1976) CGI: clinical global impressions. ECDEU assessment manual for Psychopharmacology, revised, pp 217\u2013222"},{"issue":"7","key":"1098_CR28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/j.1528-1157.1998.tb01163.x","volume":"39","author":"U Steffenburg","year":"1998","unstructured":"Steffenburg U, Hedstr\u00f6m A, Lindroth A, Wiklund LM, Hagberg G, Kyllermann M (1998) Intractable epilepsy in a population-based series of mentally retarded children. Epilepsia 39(7):767\u2013775","journal-title":"Epilepsia"},{"issue":"6","key":"1098_CR29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1055\/s-2008-1073041","volume":"25","author":"P Uvebrant","year":"1994","unstructured":"Uvebrant P, Bauzien\u00e8 R (1994) Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 25(6):284\u2013289","journal-title":"Neuropediatrics"},{"key":"1098_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1059-1311(00)90474-6","volume":"10","author":"P Crawford","year":"2001","unstructured":"Crawford P, Brown S, Kerr M, Parke Davis Clinical Trials Group (2001) A randomised open-label study of gabapentine and lamotrigine in adults with learning disability and resistant epilepsy. Seizure 10:107\u2013115","journal-title":"Seizure"},{"key":"1098_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1528-1157.1996.tb00007.x","volume":"37","author":"JA King","year":"1996","unstructured":"King JA, Knight JE, Oommen KJ (1996) Efficacy of lamotrigine in the developmentally disabled (abstract). Epilepsia 37:162","journal-title":"Epilepsia"},{"issue":"8","key":"1098_CR32","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S1059-1311(03)00101-8","volume":"12","author":"B Huber","year":"2003","unstructured":"Huber B, Tomka-Hoffmeister M (2003) Limited efficacy of gabapentin in severe therapy-resistant epilepsies of learning-disabled patients. Seizure 12(8):602\u2013603","journal-title":"Seizure"},{"issue":"3","key":"1098_CR33","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S1059-1311(03)00154-7","volume":"13","author":"B Huber","year":"2004","unstructured":"Huber B, B\u00f6mmel W, Hauser I, Horstmann V, Liem S, May T et al (2004) Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities. Seizure 13(3):168\u2013175","journal-title":"Seizure"},{"issue":"4","key":"1098_CR34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1046\/j.1528-1157.2002.47401.x","volume":"43","author":"K Kelly","year":"2002","unstructured":"Kelly K, Stephen L, Sills G, Brodie M (2002) Topiramate in patients with learning disability and refractory epilepsy. Epilepsia 43(4):399\u2013402","journal-title":"Epilepsia"},{"issue":"1","key":"1098_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/seiz.2001.0571","volume":"11","author":"BK Singh","year":"2002","unstructured":"Singh BK, White-Scott S (2002) Role of topiramate in adults with intractable epilepsy, mental retardation and developmental disabilities. Seizure 11(1):47\u201350","journal-title":"Seizure"},{"issue":"2","key":"1098_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/ane.12451","volume":"133","author":"F Rosenow","year":"2015","unstructured":"Rosenow F, Kelemen A, Ben-Menachem E et al (2015) Long-term adjunctive lacosamide treatment in patients with partial-onset seizures. Acta Neurol Scand 133(2):136\u2013144","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"1098_CR37","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1528-1157.1998.tb01373.x","volume":"39","author":"R Beran","year":"1998","unstructured":"Beran R, Gibson R (1998) Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 39(3):280\u2013282","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"1098_CR38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1046\/j.1528-1157.2001.0420s4036.x","volume":"42","author":"C Harden","year":"2001","unstructured":"Harden C (2001) Safety profile of levetiracetam. Epilepsia 42(Suppl 4):36\u201339","journal-title":"Epilepsia"},{"issue":"6","key":"1098_CR39","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/ane.12781","volume":"136","author":"E Andres","year":"2017","unstructured":"Andres E, Kerling F, Hamer H, Burkhard K, Winterholler M (2017) Behavioural changes in patients with intellectual disability treated with perampanel. Acta Neurol Scan 136(6):645\u2013653","journal-title":"Acta Neurol Scan"},{"issue":"2","key":"1098_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.yebeh.2007.09.001","volume":"12","author":"G Coppola","year":"2008","unstructured":"Coppola G, Verrotti A, Resicato G, Ferrarelli S, Auricchio G, Operto FF, Pascotto A (2008) Topiramate in children and adolescents with epilepsy and mental retardation: a prospective study on behavior and cognitive effects. Epilepsy Behav 12(2):253\u2013256","journal-title":"Epilepsy Behav"},{"issue":"3","key":"1098_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ane.12943","volume":"138","author":"E Andres","year":"2018","unstructured":"Andres E, Kerling F, Hamer H, Winterholler M (2018) Behavioural changes in patients with intellectual disability treated with brivaracetam. Acta Neurol Scand 138(3):195\u2013202","journal-title":"Acta Neurol Scand"},{"key":"1098_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.yebeh.2016.02.007","volume":"57","author":"N Foldvary-Schaefer","year":"2016","unstructured":"Foldvary-Schaefer N, Fong J, Morrison S et al (2016) Lacosamide tolerability in adult patients with partial-onset seizures: impact of planned reduction and mechanism of action of concomitant antiepileptic drugs. Epilepsy Behav 57:155\u2013160","journal-title":"Epilepsy Behav"},{"key":"1098_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.yebeh.2010.10.002","volume":"20","author":"J Novy","year":"2011","unstructured":"Novy J, Patsalos PN, Sander JW et al (2011) Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav 20:20\u201323","journal-title":"Epilepsy Behav"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01098-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-019-01098-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01098-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:09:53Z","timestamp":1583366993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-019-01098-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1007\/s13760-019-01098-3","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"20 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Anika Kleist declares that she has no conflict of interest. Frank Kerling and Hajo Hamer have received honoraria from Eisai, UCB, Desitin, Novartis, Glaxo Smith Kline, Janssen Cilag, Pfizer, Sanofi Aventis. Martin Winterholler declares that he has no conflict of interest. All data generated and analysed during the current study are included in this published article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Furthermore, the study was approved by the Ethics Committee of the University of Erlangen-Nuremberg (Ethics vote no. 290-14Bc).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants or their legal representatives included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}